Immunogenicity and clinical activity of Tipapkinogen sovacivec (TG4001), an HPV-16 cancer vaccine: a randomized phase 2 study in recurrent or metastatic (R/M)  anogenital cancers

C. Le Tourneau, et al.
ASCO 2023 
Abstract available on the ASCO website – Download the abstract and the poster
Poster Presentation